TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must give written informed consent.~* Male or female subjects, 18 years of age.~* Confirmed diagnosis of Crohn's Disease.~* Subject must have a 3 month documented history of perianal Crohn's Disease (PCD) and with clinical evidence of active PCD.~* Subject must have a Crohn's Disease Activity Index (CDAI) total score of ≤ 350 at Visit 2.~* Subjects must have a qualifying perianal pain score at Visits 1 and 2.~Exclusion Criteria:~* Women of childbearing potential who are not using adequate contraception.~* Women who are pregnant or breastfeeding.~* Subjects on unstable regimens of Crohn's therapy (e.g. tumor necrosis factor (TNF) inhibitors, immunosuppressants, steroids).~* Subjects taking strong analgesics that could interfere with pain measurements. Subjects with a perianal abscess requiring incision and drainage.~* Subjects with anal stenosis.~* Subjects with fistulae outside the immediate perianal area.~* Subjects who have had abdominal surgery for Crohn's disease within the past 12 weeks.~* Subjects who have had significant anorectal surgery for Crohns disease within the past 8 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLI-1300 (low dose) (Type: EXPERIMENTAL): Investigational Product (10%) Ointment
- BLI-1300 (high dose) (Type: EXPERIMENTAL): Investigational Product (20%) Ointment
- placebo (Type: PLACEBO_COMPARATOR): Placebo Ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The MOM TO BE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 25 - 45 kg/m2~* ≥ 21 years of age~Exclusion Criteria:~* Pre-existing conditions (e.g. sexual transmitted diseases) that will affect the outcomes of the study as determined by the principal investigator~* Current use of recreational drugs, tobacco, or alcohol~* Food allergies, intolerances or preferences which would interfere with compliance to the meal plan~* Contraindications to exercise~* Already meeting the physical activity guidelines (150 min moderate activity/week or 75 minutes of vigorous activity/week with resistance exercise on 2 or more days/week).

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diet and Exercise (Type: ACTIVE_COMPARATOR): Group 1 = Diet Intervention group: They will be asked to follow a personalized diet during study period and record what they eat. The meal plan for this study is Mediterranean style and nutritionally complete for 8 to 12 weeks or until oocyte retrieval procedure. Exercise Intervention: Exercise 3 times/week at a gym of their choice or at home for 8 to 12 weeks or until oocyte retrieval procedure. Exercises will be light intensity and short duration at first and will gradually increase to moderate intensity and longer duration during the first 3 weeks. They will also be encouraged to walk an average 10,000 steps per day and wear a pedometer to monitor progress.
- Standard Care (Type: NO_INTERVENTION): Group 2 = Standard: They will receive standard care from the Little Rock Fertility Center.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients, aged 5-17 years inclusive~* History of house dust mite-related allergic rhinitis for at least 1 year requiring regular intake of symptomatic treatment(s)~* Sensitised to D. pteronyssinus and/or D. farinae (positive skin prick test with wheal diameter greater than 3 mm and specific IgE level ≥ 0.7 kU/L)~Exclusion Criteria:~• Co-sensitization associated with clinically relevant allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study (that means patient symptomatic to another allergen than house dust mites to which the patient will be exposed during the study, i.e. will notably be excluded~* patients sensitised to cat or dog allergens and regularly exposed to these allergens~* patients sensitised to aspergillus, cladosporium, alternaria~* patients sensitised to parietaria , ragweed, or mugwort, if this allergen is endemic to the region

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Dpte and Dfar Allergen Extract (Type: ACTIVE_COMPARATOR): None
- Placebo tablets (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: What is the Predictive Value of the Reflux Impact Scale

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Patients with symptoms of reflux disease and or regurgitation and/or retrosternal pain probably caused by acid during the previous 7 days and for which treatment with a PPI is started.~Exclusion Criteria:~* Use of PPI and/or H2-receptor antagonist in the month prior to participation in this study.~* Presence of alarm symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CleanUP IPF for the Pulmonary Trials Cooperative

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 40 years of age~2. Diagnosed with idiopathic pulmonary fibrosis (IPF) by enrolling investigator~3. Signed informed consent~Exclusion Criteria:~1. Received antimicrobial therapy in the past 30 days~2. Contraindicated for antibiotic therapy, including but not exclusive to:~   1. Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or their combination~  2. Allergy or intolerance to tetracyclines AND known potassium level \> 5 mEq/L in the past 90 days.~      * If the enrolling physician feels the potassium level has normalized, documentation to that effect must be provided.~  3. Allergy or intolerance to tetracyclines AND concomitant use of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), potassium sparing diuretic, dofetilide, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide~  4. Allergy or intolerance to tetracyclines AND known glucose-6-phosphate dehydrogenase deficiency~  5. Allergy or intolerance to tetracyclines AND untreated folate or B12 deficiency~  6. Allergy or intolerance to tetracyclines AND known renal insufficiency (defined as a glomerular filtration rate (GFR) \< 30 ml within the previous 90 days)~      * If the enrolling physician feels the renal dysfunction has resolved, documentation to that effect must be provided.~3. Pregnant or anticipate becoming pregnant~4. Use of an investigational study agent for IPF therapy within the past 30 days, or an IV infusion with a half-life of four (4) weeks.~5. Concomitant immunosuppression with azathioprine, mycophenolate, cyclophosphamide, or cyclosporine.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antimicrobial therapy (Type: EXPERIMENTAL): Co-trimoxazole OR doxycycline
- Standard of care (Type: OTHER): Standard of care for patients with IPF for comparison

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed malignant mesothelioma that is not amenable to curative surgery At least 1 unidimensionally measurable lesion that is at least 15 mm by CT scan OR At least 1 bidimensionally measurable lesion that is at least 10 mm by CT scan Lesions in previously irradiated area are not considered measurable unless there is evidence of progression No symptomatic brain or leptomeningeal involvement~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 OR Karnofsky 70-100% Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than upper limit of normal (ULN) Alkaline phosphatase no greater than ULN unless bone metastases are present AST/ALT no greater than 2.5 times ULN Albumin at least 2.5 g/dL No chronic active liver disease Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 40 mL/min Cardiovascular: No uncontrolled heart disease No uncontrolled hypertension Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for one month after study No other serious illness or medical condition No history of significant neurological or psychiatric disorders No significant active infection No other concurrent neoplastic disease except non-melanoma skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY: Biologic therapy: No prophylactic hematopoietic colony-stimulating factors (e.g., filgrastim (G-CSF) or sargramostim (GM-CSF)) Chemotherapy: No prior systemic chemotherapy No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least 30 days since prior radiotherapy and recovered No concurrent radiotherapy except palliative local radiotherapy to non-target lesions Surgery: See Disease Characteristics At least 14 days since prior pleurodesis Recovered from prior surgery Other: At least 30 days since prior participation in another therapeutic clinical trial or therapy with other investigational drugs No concurrent treatment for other neoplastic disease No other concurrent experimental anticancer medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Low-Level Laser Stimulation on Hearing Thresholds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* bilateral sensorineural hearing loss~* normal middle ear status~Exclusion Criteria:~* pregnant or lactating~* serious mental health illness or medical/psychiatric hospitalization~* treatment with cancer chemotherapeutic agents or aminoglycoside antibiotics~* taking Aspirin, Ibuprofen, Naprosyn, Aleve~* taking any Quinine-related drugs~* taking any loop diuretics~* have a developmental disability or cognitive impairment~* history of drug abuse~* involved in litigation or claim related to hearing loss~* regularly exposed to significant occupational or recreational noise~* have a photosensitivity disorder~* have a retinal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low-Level Laser Therapy (Type: EXPERIMENTAL): Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
- Disabled Laser (Type: PLACEBO_COMPARATOR): Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
- Control (Type: NO_INTERVENTION): Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Differential Diagnosis of Pulmonary Hypertension With Automated Image Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with right-heart catheterization~* Clinical indication for thoracic CT~Exclusion Criteria:~* Pregnancy~* Decreased kidney function~* Intolerance to contrast material~* Other standard CT contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Pulmonary arterial hypertension (PAH) (Type: None): The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
- PH due to left-heart disease (PH-LHD) (Type: None): The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
- Chronic thromboembolic pulmonary hypertension (CTEPH) (Type: None): The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
- PH due to emphysema (PH-LD-Emphys) (Type: None): The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
- PH due to lung fibrosis (PH-LD-Fibr) (Type: None): The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
- PH due to combined emphysema and fibrosis (PH-LD-CPFE) (Type: None): The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
- No PH (Type: None): The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients aged 18 years and above undergoing first ERCP procedure~Exclusion Criteria:~* Active acute pancreatitis,~* Lower end malignant bile duct block,~* Patients undergoing repeat procedures,including those with previous sphincterotomy~* Ongoing therapy with nitrates, calcium channel blockers, somatostatin or octreotide~* Patients with bleeding diathesis.~* Patients with chronic pancreatitis~* Patients with cardiac comorbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Valdecoxib
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed breast cancer scheduled to receive chemotherapy with doxorubicin and cyclophosphamide (adjuvant or neoadjuvant)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Projected life expectancy of at least 3 months~* Provision of informed consent prior to any study-related procedures~* Negative pregnancy test for women of childbearing potential~* Absolute neutrophil count (ANC) \>= 1500/mm\^3~* Platelet count \>= 100,000 cells/mm\^3~* Hemoglobin \>= 9.0g/dL~* Serum creatinine =\< 1.5 mg/dl~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 X upper limit of normal (ULN)~* Alkaline phosphatase =\< 2.5 X upper limit of normal; in patients with bone metastasis and no evidence of liver metastasis and bilirubin =\< upper limit of normal an alkaline phosphatase =\< 5 ULN will be allowed~* Serum bilirubin =\< 1.0 mg/dL~* No other concomitant therapy directed at the cancer is allowed~Exclusion Criteria:~* Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone~* Use of another antiemetic agent (5HT3 antagonists, phenothiazines, butyrophenones, cannabinoids, metoclopramide, or corticosteroids) within 72 hours prior to day 1 of the study~* Use of anticoagulant agent (Warfarin, Coumadin, Jantoven, Marevan, Lawarin, Waran, or Warfant)~* An episode of vomiting or retching within 24 hours before the start of the initial treatment with chemotherapy~* Severe concurrent illness other than neoplasia~* Gastrointestinal obstruction or an active peptic ulcer~* Patients who are pregnant or breast feeding because aprepitant may be harmful to the developing fetus and newborn

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (antiemetics) (Type: EXPERIMENTAL): Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Innovation in NOn Invasive Ventilation in COPD Patients Treated by Long Term Oxygen Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic obstructive pulmonary disease (COPD)~  * on long term oxygen therapy (LTOT)~ * affiliated to French social security system or equivalent~ * informed consent signed~Exclusion Criteria:~* Diurnal PtCO2 \>55mmHg~* Patient who has had an exacerbation of COPD requiring a change in management or treatment in the last 4 weeks prior to the inclusion visit.~* Pregnant or breathfeeding women~* Prisonners or persons who require protection by the law~* Exclusion period from another study~* Persons who, according to the investigator, are expected no to meet all study obligations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NIV Device + LTOT (Type: EXPERIMENTAL): administration of ventilary support, without using an invasive artificial airway
- LTOT (Type: ACTIVE_COMPARATOR): standard treatment, without NIV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues